Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative.
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s closing price, and a CVR re
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to 12,669.27. The S&P 500, also rose, gaining, 0.08% to 4,195.41.
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea Pharmaceuticals will report an earnings per share (EPS) of $-0.44.
